Skip to main content
Kolon TissueGene, Inc. logo

Kolon TissueGene, Inc. — Investor Relations & Filings

Ticker · 950160 ISIN · KR8840120008 LEI · 5493000SYYLC88FUL781 KO Manufacturing
Filings indexed 288 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing KO 950160

About Kolon TissueGene, Inc.

https://www.tissuegene.com/

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is the full “분기보고서” (quarterly report) for the period January 1, 2026 to March 31, 2026 (the 28th fiscal period). It includes comprehensive financial statements (summary financial information, consolidated financial statements, notes), business descriptions, management discussion and analysis, audit opinions, and other substantive report sections. It is not merely an announcement or presentation but the actual interim/quarterly financial report. Therefore, it matches the Interim / Quarterly Report category (IR). Q1 2026
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a statutory insider shareholding report (“임원·주요주주 특정증권등 소유상황보고서”) filed with the Financial Supervisory Commission and Korea Exchange, detailing an officer/major shareholder’s holdings and specific securities transactions (dates, quantities, pre- and post-holdings). This matches the definition of a Director’s Dealing/insider transaction report, not an earnings, board change, or general regulatory announcement.
2026-05-15 Korean
파생상품거래손실발생
Regulatory Filings Classification · 82% confidence The document is a regulatory disclosure in Korean announcing a derivative product trading loss under K-IFRS. It provides detailed loss figures, capital impact, and explanatory notes but does not constitute an earnings release, financial report, or investor presentation. It is an ad hoc compliance announcement, fitting the fallback category for general regulatory filings (RNS).
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 95% confidence The document is a Korean statutory ‘임원ㆍ주요주주 특정증권등 소유상황보고서’, detailing changes in share ownership by a major shareholder (Kolon Corporation) in Kolon TissueGene, Inc., including quantities, acquisition dates, and percentages. This corresponds to a Major Shareholding Notification rather than an earnings release or management report.
2026-03-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 92% confidence The document is a statutory ‘주식등의 대량보유상황보고서’ (Large Shareholding Status Report) filed under the Korean Capital Markets Act (reporting large shareholdings and threshold crossings). It details share quantities, ownership percentages, changes due to conversions and third-party allocations, and is clearly a major shareholding notification rather than financial results, management changes, or an annual report.
2026-03-27 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 88% confidence The document is a corporate disclosure titled “사외이사의 선임·해임 또는 중도퇴임에 관한 신고” detailing the appointment and resignation of outside directors. It is a board/management change announcement, not a full annual or interim report, financial supplement, or other regulatory filing. Therefore it fits the Board/Management Information category (MANG).
2026-03-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.